Evidence map›Paper›PMID 37561249›Full record

ArticleInternational ophthalmology2023

Changes in therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy.

Mariya Asenova Stoynova, Alexander Dimitrov Shinkov, Miroslav Todorov Novoselski, Victoria Vladimirova Petrova, Inna Dimitrova Dimitrova, Inna Angelova Yankova, Roussanka Dimitrova Kovatcheva

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05775185 (Changes in Therapeutic Response, Ocular Manifestations of Graves' Orbitopathy and Quality of Life During the First Year After Orbital Radiotherapy), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05775185 completednot on this map

Changes in Therapeutic Response, Ocular Manifestations of Graves' Orbitopathy and Quality of Life During the First Year After Orbital Radiotherapy

Typeobservational_patient_registrySponsorMedical University of SofiaRan2017 to 2021Enrolled26ConditionsGraves OphthalmopathyArmsOrbital radiotherapy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mariya Asenova StoynovaDepartment of Endocrinology, Medical University of Sofia, University Hospital of Endocrinology, 2 Zdrave Str., 1431, Sofia, Bulgaria. mariya.stoynova@abv.bg.ORCID http://orcid.org/0000-0003-1355-9551
Alexander Dimitrov ShinkovDepartment of Endocrinology, Medical University of Sofia, University Hospital of Endocrinology, 2 Zdrave Str., 1431, Sofia, Bulgaria.ORCID http://orcid.org/0000-0002-9203-4149
Miroslav Todorov NovoselskiDepartment of Radiooncology, Medical University of Sofia, University Hospital "Tsaritsa Yoanna", Sofia, Bulgaria.ORCID http://orcid.org/0009-0004-6846-6330
Victoria Vladimirova PetrovaDepartment of Ophthalmology, Medical University of Sofia, University Hospital of Endocrinology, Sofia, Bulgaria.ORCID http://orcid.org/0009-0002-1173-1821
Inna Dimitrova DimitrovaDepartment of Endocrinology, Medical University of Sofia, University Hospital of Endocrinology, 2 Zdrave Str., 1431, Sofia, Bulgaria.ORCID http://orcid.org/0000-0001-7190-5008
Inna Angelova YankovaDepartment of Endocrinology, Medical University of Sofia, University Hospital of Endocrinology, 2 Zdrave Str., 1431, Sofia, Bulgaria.ORCID http://orcid.org/0000-0002-0416-4091
Roussanka Dimitrova KovatchevaDepartment of Endocrinology, Medical University of Sofia, University Hospital of Endocrinology, 2 Zdrave Str., 1431, Sofia, Bulgaria.ORCID http://orcid.org/0000-0003-1894-8433

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of our study was to assess the changes in the therapeutic response, ocular manifestations of GO and quality of life during the first year after OR.

methodsThe study involved 26 consecutive patients with active moderate-to-severe GO indicated for OR, 18 females, mean age 57 ± 12.5. At baseline, all patients underwent comprehensive ocular examination and thyroid hormone and antibody testing. Then, OR was performed with a total dose of 20 Gy, divided into 10 sessions of 2 Gy each with concomitant oral intake of low-dose glucocorticoids. Therapeutic response and individual ocular manifestations were evaluated 1, 3, 6 and 12 months after OR, and QoL-at 3, 6 and 12 months by a disease-specific questionnaire.

resultsOne month after OR, 61.6% of patients had a therapeutic response (full or partial). During the follow-up, the proportion of full-responders gradually increased up to 57.5% at 12 months, while that of non-responders gradually decreased, reaching 11.5% at 12 months. All individual ocular manifestations improved significantly 1-3 months after OR. QoL related to visual functioning increased significantly at 6 months, whereas QoL related to appearance improved significantly at 12 months.

conclusionsThe vast majority of our patients with active moderate-to-severe GO exhibited full or partial therapeutic response after OR. The initial effect on the therapeutic response and individual ocular parameters was evident as soon as 1-3 months after the procedure. OR also has a beneficial effect on patients' QoL. TRIAL REGISTRATION NUMBER: NCT05775185/07.03.2023, retrospectively registered.

Indexed as

Graves OphthalmopathyAdultAgedFemaleGlucocorticoidsHumansMiddle AgedQuality of LifeGlucocorticoidsEfficacyGraves’ orbitopathyOcular parametersOrbital radiotherapyQuality of lifeTherapeutic response

Identifiers

PMID37561249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.